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ing task with five trials and an interference list (15 new words – List B) read to the
subject after the fifth trial of List A. The original RAVLT also includes a recognition
trial in which subjects are asked to identify List A words from a larger list of words
that includes distractor words. In most versions of the RAVLT, the distractor list is
comprised of words from List B as well as other words, most having either a se-
mantic and/or a phonetic link with words from Lists A and/or B. The objective of
this abstract is to present the translation process of the RAVLT into US Spanish (six
pairs of recall lists and six recognition lists). METHODS: For the recall words, a
direct translation, in collaboration with a speech therapist and a neuropsycholo-
gist, was recommended, with frequency of use similar to the original as well as
word length (1 syllable or 2 syllables and 2 characters). For the recognition
words, the translations had to respect the semantic and phonetic links to the recall
words. RESULTS: Fifty out of 180 words from the recall lists raised discussions
because of difficulties in finding translations with the appropriate word length.
Thirty-four out of 120 words from the recognition list proved difficult to translate
because of problems in finding direct translations that respected the phonetic or
semantic links to the recall words. For instance, the recognition word “Balloon,”
with a phonetic link with “Moon” (List A #1), was “translated” as “Lona” (Tarp) to
keep the phonetic link with “Luna” (Moon). CONCLUSIONS: This methodology en-
abled production of a US Spanish version of the RAVLT respecting the intent of the
original US English.
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OBJECTIVES: To review the methodology of studies evaluating pregnancy/birth/
child development outcomes of prenatal antidepressant exposure (PAE) and, when
appropriate, assess the impact on study results usingmeta-regression.METHODS:
A Medline search was conducted up to October 2011, restricting to English and
human literature. The MeSH term “antidepressive agents,” was combined with
MeSH terms for spontaneous abortion, preterm birth(PB), birth weight, small for
gestational age, or poor child development. We added relevant articles from refer-
ence lists of reviews and included studies. We proposed that antidepressant class,
type of data source, adjustment for maternal depression, exposure definition, du-
ration and timing, and adjustment for more than three covariates would impact
study results. Cochran’s Q statistic was used to test for heterogeneity of results.
When heterogeneity existed, meta-regression using a random-effects model was
performed to examine the impact of different methodological choices on study
results. Meta-regression is a regression analysis in which each study is a unit of
observation and the effect estimate is regressed on study characteristics.RESULTS:
Of 33 studies included, we found differences in the definition of PAE, data sources,
and covariates adjusted. Thirteen studies focused on selective serotonin reuptake
inhibitors. Five studies defined exposure as one prescription of antidepressant
during pregnancy versus 13 studies required PAE for at least one trimester. Preg-
nancy information services, birth registries, and referrals from hospitals/clinics
were the most common data sources. Only 10 studies adjusted for maternal de-
pression. Cochran’s Q was only significant for PB. Meta-regression showed that
adjusting for more than three covariates significantly (p0.02) impacted pooled
odds ratios (POR). POR for PB was 1.39 (95% confidence interval (CI)1.27-1.52) for
studies with 3 or more covariates versus 1.82(95% CI1.43-2.29) for other studies.
CONCLUSIONS: Methodological variations can make pooling of observational
studies inappropriate. Consistency of study methodology should be assessed be-
fore combining studies even if heterogeneity were absent.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
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OBJECTIVES: To estimate hospitalization costs attributable to obesity (CAO) in pa-
tients with adverse drug events (ADE) in the US hospital. METHODS: The study
used the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization
Project (HCUP) from 2001 to 2009. The NIS includes sampling weight and design
variable for generating national representative estimates. ADE were defined as
poisoning due to inappropriate uses or medication errors, and an adverse drug
reaction. The cost to charge ratios were applied to estimate hospitalization costs
using the hospital charge. The recycled prediction method was employed to esti-
mate CAO. This method estimated parameters by running a generalized linear
model with log link function and gamma distribution of hospital costs on all the
study variables. CAO was defines as the differences between the predicted mean
hospitalization costs for obese patients with ADE and the predicted mean hospi-
talized costs if obese patients with ADE could be a normal weight patients with
ADE. All costs were converted to 2010 US dollars. RESULTS: A total of 2,177,755
admissions due to ADE were identified. Among these admissions, 4.3% of them
were obese patients. Obese patients were older than non-obese patients (46.6 vs.
43.7, p0.001) and stayed longer in hospital than non-obese patients (3.4 vs. 2.9
days, respectively). The average hospitalization costs were $9099 (95%CI:$8,926-
$9272) for obese and $8014 (95%CI:$7978-$8051) for non-obese patients. Overall, the
average CAO in patients with ADEwas predicted to be $725 (95%CI:$720-$729) after
adjusting for patients characteristics and comorbidities. CAO were increased as
patients age increased from $457 (95%CI:$446-$468) for age 0-17 years old to
$1,051($993-$1,110) for age85years old. CONCLUSIONS: Obese patients with ADE
have significantly higher hospitalization costs compared to non-obese patients
with ADE. Since the additional costs due to obesity are avoidable, the additional
efforts to lose weight are strongly recommended.
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OBJECTIVES: To quantify the incidence of adverse events (AEs), identify discontin-
uation rates due to AEs, and determine the cost and resource use associated with
AEs from azathioprine (AZA), cyclophosphamide (CYC), mycophenolate mofetil
(MMF),methotrexate (MTX), and cyclosporine (CsA) in patientswith systemic lupus
erythematosus (SLE). METHODS: A systematic review of English-language, MED-
LINE- and EMBASE-indexed literature published between January 1980 and Sep-
tember 2011 was conducted using terms related to SLE, AEs, discontinuation, re-
source use and costs.RESULTS:This review identified 38 publications reporting the
burden of AEs related to AZA, CYC, MMF, MTX or CsA. The incidence of AEs ranged
from 42.8% to 97.3%. Common AEs included infections, gastrointestinal AEs and
amenorrhea. In direct comparisons, AZA was associated with more hematological
cytopenias than MMF (26.9% vs. 3.8%, respectively) based on one study. CYC was
associated with more infections than MMF (40-77% vs. 12.5-32%, respectively) or
AZA (17-77% vs. 11-29%, respectively), and it was also related tomore gynecological
toxicities than MMF (32-36% vs. 3.6-6%, respectively) or AZA (32-71% vs. 8-18%,
respectively). However, other studies reported no difference in AEs associatedwith
CYC compared to either AZA or MMF, or with AZA compared to CsA. Discontinua-
tion rates due toAEswere 0–17% in short-term randomized controlled trials (RCTs),
2.3–44.4% in long-term RCTs, and 1.9–21.8% in observational studies. The rate of
hospitalized infections was similar between patients taking MMF and AZA (1 day
per patient-year in each group), but higher for those taking CYC (10 days per pa-
tient-year). No studies reported costs associated with AEs. CONCLUSIONS: The
incidence of AEs associatedwith SLE immunosuppresantswas consistently high as
reported in the SLE literature,while discontinuation due to theseAEswidely varied.
Studies describing costs and resource use associated with these AEs were sparse
and warrant further study.
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OBJECTIVES: Anti-tumor necrosis factor (TNF) medications have revolutionized
the treatment of autoimmune diseases. They are associated, however, with a wide
range of serious adverse events (AE). The objectives of this study were to describe
the potential serious AEs associatedwith anti-TNFmedications and compare them
with the AEs associated with concomitant use of methotrexate and corticosteroids
in US.METHODS:The study anti-TNFmedications included infliximab, etanercept,
adalimumab, certolizumab pegol and golimumab. The FDAAdverse Events Report-
ing System (AERS) database was utilized to determine the overall frequency of
adverse events involving anti-TNF medications. The data from 1998 to 2010 were
used to analyze the trend of AEs. Due to the complexity of the database, AEs re-
ported in 2009, were selected for detailed measurement and comparison as a per-
cent of reported events within the drug classes. All AEs involving anti-TNF medi-
cations, corticosteroid and methotrexate (MTX) monotherapy and in combination
with MTX and/or corticosteroids were analyzed and compared in this analysis.
RESULTS: A substantially higher number of AEs were reported for anti-TNF medi-
cations compared tomethotrexate or corticosteroidmonotherapy. A total of 36,245
AE reports in 2009, including 24,166 (67%) for anti-TNF, 6,164 reports for anti-TNF/
MTX and 2,867 for anti-TNF/corticosteroids. There was an increased frequency for
a range of anti-TNF-associated AEs among those patients who were also taking a
combination of anti-TNF plus corticosteroid and an even greater increase in pa-
tients taking the three drug combination (anti-TNF/MTX/corticosteroid). Themajor
reported AEs associated with anti-TNF are infectious complications, cancer risk,
death or disabling outcome, neurological and cardiac pathology. CONCLUSIONS:
There is a significant risk of AE associated with anti-TNF and the proportion of AEs
may behigher if patients received combination therapywithMTXor corticosteroid.
It is important to have a drug safety sentinel for unknown AEs associated with
anti-TNF agents.
PSY4
PREVALENCE OF AUTOIMMUNE DISEASES AND OTHER COMORBIDITIES IN
PATIENTS WITH PSORIASIS IN THE UNITED STATES
Zhang F1, Guerin A2, Gauthier G2, Day R1, Khan Z1
1Celgene Corporation, Summit, NJ, USA, 2Analysis Group, Ltee., Montreal, QC, Canada
OBJECTIVES: To estimate the comorbidity burden of patients with Pso, with a
particular focus on autoimmune diseases.METHODS: In a large US representative
administrative claims database (2004-2008), we identified adult patients with 2
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